Search
Showing results for "Professor"
News & Events
ORIGINS family finds comfort and communityA Quinns Rocks family who became the 1000th family to sign up for the ORIGINS Project is excited to be contributing to such ground-breaking research.
News & Events
Meningococcal research paves way for vaccine useA series of The Kids Research Institute Australia studies looking at safety for Meningococcal ACWY vaccines in children has led the way for its use in Australia.
News & Events
The Kids Research Institute Australia researchers share in State Government science grantsFour The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.
News & Events
New building brings research closer to the bedsidePerth's The Kids for Child Health Research will be located in an integrated building with the state's new children's hospital
News & Events
Telethon Institute Researchers Win National FundingTelethon Institute Researchers Win National Funding
News & Events
Aboriginal Health Researchers Win Major Discovery Grantsesearchers from Perth's Centre for Research Excellence in Aboriginal Health and Wellbeing have won more than $1.3 million in competitive funding
News & Events
Heath Ledger Career Development ScholarshipsFive outstanding researchers have been awarded the inaugural Heath Ledger Career Development Scholarships
Research
A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of ageJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Estimating the Impact And Costs of Antimicrobial Resistance (AMR) at Perth Children’s HospitalAMR is a rapidly growing challenge and has been identified as one of the World Health Organizations top 10 global health threats, with the potential to undo many of the health gains observed over the last century.
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical